Navigation Links
NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Date:10/25/2007

gents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability. It can also be used to modify pharmaceutical agents to preferentially target certain systems within the body. It is a technique in which non-toxic polyethylene glycol (PEG) polymers are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs.

Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of the company's PEGylation technology platform and NKTR-102. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) preclinical testing and clinical trials for NKTR-102 are long, expensive and uncertain processes, (ii) because the NKTR- 102 product development programs are in the early phases of clinical development, the risk of failure is high and can occur at any stage of development, (iii) the company may fail to obtain regulatory approval of NKTR- 102, (iv) pot
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ariz. , July 10, 2014   Ventana ...  Group, today announced it has entered into an agreement ... which operates as EMD Serono in the ... , to collaborate with Merck KGaA,s biopharmaceutical division on ... for an undisclosed target using Ventana,s proprietary diagnostic assays. ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... NEW YORK, Sept. 28, 2011 Visionsense Corp announces ... was used in its 500th neurosurgical procedure with the ... (Al Lerner Chair and Vice-Chairman, Dept of Neurosurgery at ... performed a transsphenoidal resection of a pituitary adenoma in ...
... Sept. 28, 2011 As part of its ongoing work ... settings, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its ... event and global MRSA summit will be held on October ... Maywood, Ill. Organized by the MRSA Survivors ...
Cached Medicine Technology:Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day on October 1 2
(Date:7/11/2014)... MA (PRWEB) July 11, 2014 ... at least $50 billion in fuel costs ... immediately. The current GHG standards ... have taken it upon themselves to install ... include: , 1.    Idle reduction technologies , 2.    Efficient ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down ... the Concord Pavilion . When it comes to the summer ... Bryan. The 37-year-old Georgia native is one of the biggest names ... entertainment business. Bryan is currently out on his “That’s My Kind ... many stops the tour will be making through the rest of ...
(Date:7/11/2014)... Global enterprises today are shifting towards ... management activities. Managed services offer these global enterprises a ... slowdown resulted into rising operational costs to companies. The ... to be the global market driver for expanding the ... managed services market is estimated to grow from $142.75 ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... (HealthDay News) -- Delaying surgery to repair damage to the ... middle of the knee -- could increase a young athlete,s ... medical records of 130 patients, aged 8 to 16, who ... less than six weeks after their injury, 37 had surgery ... more than three months after their injury. The youngsters ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... even flying in business class can put people at ... flights.// ,The link between blood clots (venous ... War II, when doctors noticed a rise in fatal ... in London air raid shelters. The association was further ...
... simple new test to detect kidney cancer in its ... report published in this week’s Cancer Research, researchers outline ... urine., ,Kidney cancer accounts for about 3 percent ... the United States in 2003. Doctors currently use several ...
... Programs run by nurses and dieticians have been found ... analysis has shown they work only when these health ... ,Researchers looked at a program in which patients received ... by nurses and dieticians on factors aimed at improving ...
... A new study reveals that a tonsillectomy procedure using ... key to reducing pain during recovery. // ... scalpel heats tissue as it goes along to control ... less energy to achieve the same result, which means ...
... New research shows the drug efalizumab may reduce symptoms ... ,Researchers from Loyola University studied more than 550 ... efalizumab (Raptiva) or a placebo for three months. Researchers ... the degree of scaling and thickness. Patients also completed ...
... publishing in the most recent issue of The Lancet ... for the deadly Ebola virus.// ,In a ... a factor known to inhibit blood coagulation called rNAPc2 ... kills its victims by causing severe hemorrhagic fever. This ...
Cached Medicine News:
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... have met the challenges of the ... exceptional performance and quality, they have ... worldwide. These grafts require no preclotting, ... infection, and ensure utmost thrombectomy safety. ...
... the challenges of the most demanding vascular ... exceptional performance and quality, they have earned ... grafts require no preclotting, resist dilatation and ... thrombectomy safety. Gore vascular grafts are also ...
... the newest vascular graft offering from W. ... vascular surgical products for more than two ... and compression problems that can lead ... all of the benefits of a ring ...
Medicine Products: